wxdog
1 week ago
Where the hell is ole Joey boy? No Kidding? Must of skipped out on the ole Official Documents that companies have to file to stay current with the SEC. IMO
Not a Joke Man!
Starting on page 42:
[MANAGEMENT
Directors and Executive Officers
The following table and biographical summaries set forth information, including principal occupation and business experience about our directors, director nominees and executive officers:
Name Position Age Director or Officer Since
Michael F. O’Shea Chief Executive Officer, Director 73 2020
Jason Householder Director 40 2020
Steve Gravely Director 72 2020
Jon Wilken Director 73 2022
Dr. Anja Glisovic Interim Chief Science Officer 45 2020
Michael F. O’Shea-CEO, President, Director, & Chairman. Mr. O’Shea was appointed as our Chief Executive Officer and as a director in May 2020. He is a forensic accountant and a licensed private investigator. Since 1999, Mr. O’Shea has been the Director of Forensic Research Group, Inc. and has been responsible for implementing and supervising its forensic accounting, financial investigation, and corporate due diligence programs. He has worked closely with such agencies as the Federal Deposit Insurance Corporation, Resolution Trust Corporation, FBI, Office of the Controller of the Currency, US Secret Service and ATF. He has been admitted, on numerous occasions, as an expert witness in forensic accounting in both Federal and State court as well as foreign jurisdictions. He has on several occasions been appointed as a Receiver by the State Court in South Carolina and Florida. From 1985-1998 he served as Director of Investigations for Investigative Research Group, Inc., a firm that specialized in corporate due diligence, asset searches, bankruptcy review, and loan recovery. He has been devoting a majority of his time to our affairs and expects to devote a significant amount of his time to our business following this offering.
Steve Gravely-Director. Steve Gravely was appointed as a director in July 2020. Since 2003 he has been President of the Consulting Group of Jocassee, Inc. He has been responsible for the start-up of 25 manufacturing plants around the world and over 300 new product introductions for large corporations such as Michelin, AT&T, NCR, Fluor/Maruti (India), and Fluor/General Motors. Mr. Gravely’s other prior business experience includes holding the positions of the R&D Computer Systems Integration Manager for NCR in the testing and design development of new PC's and the Director of Operations for AT&T’s Global Information Solutions (NCR) for both North American and South America, where he was responsible for the operation of manufacturing facilities in Brazil, California, and South Carolina. He graduated from Clemson University with a BS in Industrial Engineering in 1973. He devotes only such time as necessary to our affairs.
Jason Householder–Director. Jason Householder was appointed as a director in December 2020. In May 2018, he co-founded and has been CEO of Charlotte based LenDRgroup Consulting, a company providing financing to dentists, physicians, and veterinarians in South Carolina. In addition, since 20__ he has been the Manager of House Holdings LLC,, Charlotte, SC, a business consulting firm. He has over 15 years’ experience in the healthcare and banking sectors and specializes in assisting medical, dental, and veterinary practices to devise strategies that to run their businesses effectively and achieve peak performance.. He devotes only such time as necessary to our affairs.
Jon Wilken – Director. Mr. Wilken was appointed as a director in May 2022. In addition to his position as a director of our Company, since 2008 he has been President and CEO of HS Pharmaceuticals, a company engaged in oncology research and the development of human and animal health care and medical products, as well as cosmetics and beauty products. Prior to founding HS Pharmaceuticals, Mr. Wilken was President and CEO of BILO Inc., a supermarket chain which at the time of his employment was wholly owned by Ahold NV of The Netherlands. During his tenure the company employed approximately 26,000 people and operated over 400 retail supermarkets and convenience stores in four Southeastern States with annual sales of approximately $4 Billion.
Dr. Anja Glisovic-Rösch (née Glisovic)-Interim Chief Science Officer. Dr. Glisovic-Rösch was appointed as our Chief Science Officer in September 2020. Since 2008, she has been R&D Project Leader for the Fraunhofer Institute, one of the world’s leading applied research organizations. She holds numerous patents in the fields of medical devices, chemical engineering, and small arms and munitions. Dr. Glisovic received her PhD in X-Ray and Material Physics from Germany’s Georg-August Universität in 2007. She devotes only such time as necessary to our affairs.
42
Director Nominees. Upon effectiveness of this offering the following persons have agreed to being appointed as directors of our Company. Except for Mr. O’Shea, who will remain in his current positions, the current directors have agreed to resign.
Katherine Beebe DeVarney, Ph.D, will be appointed as a director of our Company on the effective date of this prospectus. Since 2007 Dr. DeVarney has been employed by Titan Pharmaceuticals Inc. (NASDAQ: TTNP), a US pharmaceutical company. She originally joined Titan in February 2007 and currently serves as its President and Chief Operating Officer. She has been a member of the Titan Board since December 2019 and is also on the Board of BioCorRx Pharmaceuticals. During her 17 years with Titan, she served in various senior executive, scientific and medical research and development capacities, with primary responsibility for oversight of product research and development, Regulatory Affairs, and Medical Affairs. Dr. DeVarney has 28 years of experience as a Neuroscientist in the pharmaceutical industry, including positions of increasing responsibility with SmithKline Beecham, GlaxoSmithKline, Merck, and Corcept Therapeutics. Prior to her pharmaceutical career, Dr. DeVarney was a hospital-based clinician and worked in academic medicine for 10 years. She received her Ph.D. in Clinical Neuropsychology from George Mason University and completed a two-year post-doctoral fellowship at Graduate Hospital and the University of Pennsylvania. Based on Dr. DeVarney’s extensive knowledge of the medical, research, and regulatory requirements of product development programs, our Board believes that Dr. DeVarney has the appropriate set of skills to serve as member of the Board.
Jervis Hough, will be appointed as a director of our Company on the effective date of this prospectus. Mr. Hough has been a brokerage professional with over twenty (20) years of proven analytical, interpretive, and communication skills in the securities industry. Since 2018 he has been employed as the Chief Compliance Officer/Chief Operating Officer/Senior Vice President of Blaylock Van, LLC, Atlanta, GA and New York. He has also been employed as a compliance examiner at FINRA, District 7, Atlanta, GA. Mr. Hough holds numerous securities licenses, including Series 7, 24, 53, 63, 79 and 99. He is a Certified Securities Compliance Professional® (National Society of Compliance Professionals) and a past associate member of the Association of Certified Fraud Examiners. Mr. Hough received an MS degree in Applied Economics from Clemson University in 2000 and a BS degree in Economics from Clemson University, John E. Walker School of Economics in 1997. Mr. Hough currently serves on the Board of Directors and Chair of the Audit Committee of Progressive Care Inc. (OTC:RXMD) and has been a Board member since August 2017. Based on Mr. Hough’s extensive experience in the securities industry and general business knowledge our Board believes that he has the appropriate set of skills to serve as member of the Board.
David Natan will be appointed as a director of our Company on the effective date of this prospectus. He will also assume the position as Chairperson of our Audit Committee of the Board. He currently serves as CEO of Natan & Associates, LLC, a consulting firm offering CFO services to public and private companies since 2007. From February 2010 to May 2020, Mr. Natan served as CEO of ForceField Energy, Inc. (OTCMKTS: FNRG), a company focused on LED lighting products. From February 2002 to November 2007, Mr. Natan served as CFO of PharmaNet Development Group, Inc., a drug development company, and, from June 1995 to February 2002, as CFO and VP of Global Technovations, Inc., a manufacturer and marketer of speaker components. Prior to that, Mr. Natan served in various roles with Deloitte & Touche LLP. From April 2020 through June 2023, Mr. Natan was Executive Vice President and Chief Financial Officer for Airborne Motorworks, Inc., Spokane, WA, a privately-held aerospace transportation company. Mr. Natan currently serves as a member of the Board of Directors and Chair of the Audit Committee of NetBrands, Inc. (OTC: NBND), a distributor of snack products, since February 2021; and Sunshine Biopharma Inc., (NASDAQ: SBFM), a Canadian pharmaceutical company. Additionally, in November 2023, Mr. Natan was appointed to the board of Directors and Audit Committee Chair of Minim Inc. (NASDAQ: MINM). Mr. Natan also has served as Audit Chair of Opgen Inc. a biotech company (Nasdaq :GPGN) since March 2024. Mr. Natan holds a B.A. in Economics from Boston University. Mr. Natan’s experience as a business executive and as a director and chairperson of audit committees for public companies qualifies him to serve on our board of directors.
Doyle B. Word will be appointed a director of our Company on the effective date of this prospectus. Since December 2021, he has been a co-manager of one of our current subsidiaries, Afyi Sasa Africa LLC. In addition, beginning in 2008 he began working with Madaktari Africa LLC, a non-profit corporation that partnered with major universities to teach neurosurgery and other medical procedures in Tanzania, where he was a member of the Board of Directors from December 2019 to the present, Chief Executive Officer from 2008 to 2014 and Director of Finance from January 2020 to the present. He graduated from Auburn University with a Bachelor of Science degree in Industrial Engineering. Based on Mr. Word’s extensive experience and knowledge of expanding medical treatment in Africa, our Board believes that he has the appropriate set of skills to serve as member of the Board.
Board of Directors
We have no formal policy regarding board diversity. In selecting board candidates, we seek individuals who will further the interests of our stockholders through an established record of professional accomplishment, the ability to contribute positively to our collaborative culture, knowledge of our business and understanding of our prospective markets.
/i]
https://www.otcmarkets.com/filing/html?id=17716303&guid=oL0-k6F-MgwfJth
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
laraz5
20 hours ago
GREGG THE GREEK
23 hours ago
findit
2 days ago
Hot Features
Premium
